PMID- 19229765
OWN - NLM
STAT- MEDLINE
DCOM- 20090521
LR  - 20090427
IS  - 1502-7732 (Electronic)
IS  - 0300-9742 (Linking)
VI  - 38
IP  - 3
DP  - 2009 May-Jun
TI  - Interleukin-18 gene (IL18) promoter polymorphisms in patients with rheumatoid 
      arthritis.
PG  - 159-65
LID - 10.1080/03009740802600748 [doi]
AB  - OBJECTIVE: Rheumatoid arthritis (RA) is a complex autoimmune disease with a 
      strong genetic contribution to its pathogenesis. Proinflammatory cytokines play 
      an important role in the inflammatory process in RA patients. The synthesis of 
      cytokines is genetically determined. Cytokine gene polymorphisms have been 
      implicated in a number of diseases, including RA. Interleukin-18 (IL-18) is a 
      proinflammatory cytokine involved in the pathogenesis of RA. There are, however, 
      controversial reports that the IL18 promoter polymorphism may be an independent 
      marker of RA susceptibility. The aim of the present study was to examine the IL18 
      promoter polymorphism in patients with RA in association with disease 
      susceptibility and activity. METHODS: We examined 404 patients with RA diagnosed 
      according to the criteria of the American College of Rheumatology (ACR). 
      Allele-specific polymerase chain reaction (PCR) and PCR restriction fragment 
      length polymorphism (RFLP) methods were used to analyse the single-nucleotide 
      polymorphisms (SNPs) rs1946518, rs187238, rs360718, rs360722, rs360721, rs549908, 
      and rs5744292 in the promoter region of the IL18 gene. RESULTS: There were no 
      significant differences in the distributions of the genotypes and haplotypes 
      between RA patients and a control group. Age at RA diagnosis was lower in 
      carriers of the rs1946518 CC and rs187238 GG genotypes. Erosive disease was 
      diagnosed more frequently in patients with the rs1946518 CC and AC genotypes than 
      in AA homozygotes. CONCLUSION: These results show that these polymorphisms in the 
      IL18 gene are associated only with some disease parameters and are generally not 
      factors significantly influencing the course of RA.
FAU - Pawlik, A
AU  - Pawlik A
AD  - Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian 
      Medical University, Szczecin, Poland. pawand@poczta.onet.pl
FAU - Kurzawski, M
AU  - Kurzawski M
FAU - Drozdzik, M
AU  - Drozdzik M
FAU - Dziedziejko, V
AU  - Dziedziejko V
FAU - Safranow, K
AU  - Safranow K
FAU - Herczynska, M
AU  - Herczynska M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/epidemiology/*genetics
MH  - Female
MH  - Genetic Predisposition to Disease/epidemiology
MH  - Genotype
MH  - Humans
MH  - Incidence
MH  - Interleukin-18/*genetics
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
MH  - Promoter Regions, Genetic/genetics
MH  - Risk Factors
MH  - Young Adult
EDAT- 2009/02/21 09:00
MHDA- 2009/05/22 09:00
CRDT- 2009/02/21 09:00
PHST- 2009/02/21 09:00 [entrez]
PHST- 2009/02/21 09:00 [pubmed]
PHST- 2009/05/22 09:00 [medline]
AID - 908868112 [pii]
AID - 10.1080/03009740802600748 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 2009 May-Jun;38(3):159-65. doi: 10.1080/03009740802600748.